Respiratory Mycoses: A Call to Action to Recognize, Educate and Invest

Armstrong‐James, Darius; Chotirmall, Sanjay H.

doi:10.1007/s11046-021-00589-3

Cited by 3 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More broadly, however, collectively, the existing evidence base does serve to confirm the clinical relevance and importance of Aspergillus -associated signatures in COPD and bronchiectasis and the urgent need to harness these signatures for improved clinical outcomes. Achieving this necessitates an improved awareness through education, accessibility through testing, and fresh approaches from a research perspective, such as that offered by novel analytics and inter-kingdom analyses [ 9 , 12 , 47 , 48 ].…”

Section: Clinical Aspergillus Signatures In Copd A...mentioning

confidence: 99%

“…Recent work by our group and others has brought about renewed interest and focus on this important knowledge gap, and demonstrates the important and underappreciated role of fungi and the mycobiome in COPD and bronchiectasis [ 5 , 7 , 8 , 9 , 10 ]. Dedicated research addressing the specific role of fungi in CRD has been highlighted as a research priority by major CRD registries and consortia, signaling global interest and the increasing emphasis on its importance as a key area of unmet need [ 11 , 12 ]. Fungi may lead to various presentations in patients with CRD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Aspergillus Signatures in COPD and Bronchiectasis

Tiew

Thng

Chotirmall

2022

JoF

Self Cite

View full text Add to dashboard Cite

Pulmonary mycoses remain a global threat, causing significant morbidity and mortality. Patients with airways disease, including COPD and bronchiectasis, are at increased risks of pulmonary mycoses and its associated complications. Frequent use of antibiotics and corticosteroids coupled with impaired host defenses predispose patients to fungal colonization and airway persistence, which are associated with negative clinical consequences. Notably, Aspergillus species remain the best-studied fungal pathogen and induce a broad spectrum of clinical manifestations in COPD and bronchiectasis ranging from colonization and sensitization to more invasive disease. Next-generation sequencing (NGS) has gained prominence in the field of respiratory infection, and in some cases is beginning to act as a viable alternative to traditional culture. NGS has revolutionized our understanding of airway microbiota and in particular fungi. In this context, it permits the identification of the previously unculturable, fungal composition, and dynamic change within microbial communities of the airway, including potential roles in chronic respiratory disease. Furthermore, inter-kingdom microbial interactions, including fungi, in conjunction with host immunity have recently been shown to have important clinical roles in COPD and bronchiectasis. In this review, we provide an overview of clinical Aspergillus signatures in COPD and bronchiectasis and cover the current advances in the understanding of the mycobiome in these disease states. The challenges and limitations of NGS will be addressed.

show abstract

Section: Clinical Aspergillus Signatures In Copd A...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical Aspergillus Signatures in COPD and Bronchiectasis

Tiew

Thng

Chotirmall

2022

JoF

Self Cite

View full text Add to dashboard Cite

show abstract

“…Aspergillus species continue to be an important cause of life-threatening infection in immunocompromised patients, particularly those under prolonged corticosteroid therapy, immunosuppressive drugs, or with hematological malignancies, or people infected with HIV or individuals suffering from AIDS [ 76 ]. Aspergillosis presents with a wide range of clinical syndromes, including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), and the most severe, invasive pulmonary aspergillosis (IPA), which is linked to high mortality rates [ 70 , 75 , 77 ] Chronic pulmonary aspergillosis has been recognized as an important and neglected fungal infection [ 78 , 79 , 80 , 81 ]. It is estimated that approximately three million cases of CPA aspergillosis occurred annually, being 2000 to 160,000 people after tuberculosis treatment, annually, with 50% case fatality in 5 years [ 82 ].…”

Section: Neglected Human Systemic Mycoses Diagnosismentioning

confidence: 99%

Challenges in Serologic Diagnostics of Neglected Human Systemic Mycoses: An Overview on Characterization of New Targets

et al. 2022

View full text Add to dashboard Cite

Systemic mycoses have been viewed as neglected diseases and they are responsible for deaths and disabilities around the world. Rapid, low-cost, simple, highly-specific and sensitive diagnostic tests are critical components of patient care, disease control and active surveillance. However, the diagnosis of fungal infections represents a great challenge because of the decline in the expertise needed for identifying fungi, and a reduced number of instruments and assays specific to fungal identification. Unfortunately, time of diagnosis is one of the most important risk factors for mortality rates from many of the systemic mycoses. In addition, phenotypic and biochemical identification methods are often time-consuming, which has created an increasing demand for new methods of fungal identification. In this review, we discuss the current context of the diagnosis of the main systemic mycoses and propose alternative approaches for the identification of new targets for fungal pathogens, which can help in the development of new diagnostic tests.

show abstract

The microbiome and COPD

Tiew,

Chotirmall

2024

COPD in the 21st Century

View full text Add to dashboard Cite

Respiratory Mycoses: A Call to Action to Recognize, Educate and Invest

Cited by 3 publications

References 46 publications

Clinical Aspergillus Signatures in COPD and Bronchiectasis

Clinical Aspergillus Signatures in COPD and Bronchiectasis

Challenges in Serologic Diagnostics of Neglected Human Systemic Mycoses: An Overview on Characterization of New Targets

The microbiome and COPD

Contact Info

Product

Resources

About